This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication
by Zacks Equity Research
Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.
Mylan (MYL) Launches Generic Version of Lilly's Adcirca
by Zacks Equity Research
Mylan (MYL) launches the first generic version of Lilly's Adcirca for the treatment of pulmonary arterial hypertension to improve exercise ability.
Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings
by Zacks Equity Research
Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.
Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y
by Zacks Equity Research
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.
AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.
Is Eli Lilly (LLY) a Great Dividend Play?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up
by Zacks Equity Research
Radius' (RDUS) Q2 results are encouraging as sales of its lead osteoporosis drug, Tymlos, continue to gain traction.
Q2 Earnings Drive Pharma ETFs Higher
by Sweta Killa
The string of strong results pushed pharma ETFs higher, with the four funds posting positive returns over the past one month.
United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip
by Zacks Equity Research
United Therapeutics (UTHR) reports unimpressive second-quarter earnings. Sales rise sequentially. Shares sink 5%.
Is a Beat in Store for Radius Health (RDUS) in Q2 Earnings?
by Zacks Equity Research
Investors will focus on lead drug Tymlos' uptake and an update on Radius Health's (RDUS) marketing application for the drug in Europe, when it reports second-quarter results on Aug 7.
Is Invesco Zacks Multi-Asset Income ETF (CVY) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CVY
Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2
by Zacks Equity Research
Incyte's (INCY) Q2 results were a mixed bag with earnings missing estimates, while revenues beating the same with growth in Jakafi's sales. A milestone payment from Eli Lilly boosted sales as well.
Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.
Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod
by Zacks Equity Research
Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.
Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength
by Zacks Equity Research
Merck (MRK) beat estimates for both earnings and sales in second-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte (INCY) has a mixed track record. Investors will focus on Jakafi sales and other pipeline updates when the company reports its Q2 results on Jul 31.
Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan
by Zacks Equity Research
Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics. The board authorizes a new $2.0 billion share buyback plan.
AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.
Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up
by Zacks Equity Research
Glaxo (GSK) beats both earnings and revenues in the second quarter of 2018, and signs a four-year collaboration with 23andMe and invests $300 million for the same.
ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions
by Zacks Equity Research
The pharma/biotech industry has witnessed a solid start in the Q2 reporting cycle. Let's see if leading players - Merck (MRK) and AbbVie (ABBV) - can contribute further to the encouraging numbers.